INmune Bio Inc. entered a license agreement with Great Ormond Street Hospital for exclusive use of clinical trial data for CORDStrom, with an upfront payment of $250,000 and a potential milestone payment of up to $6 million upon marketing authorization. The company also terminated its loan agreement with Silicon Valley Bank without any penalties or outstanding amounts.